Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger von Moos

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
Clinical Colorectal Cancer|October 1, 2016
Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term OutcomeViviane Hess, Ralph Winterhalder, Roger von Moos, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 24, 2014
Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agentsDonald L Patrick, Charles S Cleeland, Roger von Moos, et al.
Onkologie|February 23, 2013
A phase I study of the oral platinum agent satraplatin in combination with oral vinorelbine in patients with advanced solid malignanciesElisa Gallerani, Richard Cathomas, Cristiana Sessa, et al.
Journal of Bone Oncology|January 11, 2019
A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in EuropeJean-Jacques Body, Roger von Moos, Alex Rider, et al.
BMJ Open|April 18, 2023
Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)Stefanie Hayoz, Benjamin Kasenda, Annina Lea Schenker, et al.
Journal of Bone Oncology|June 13, 2018
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countriesRoger von Moos, Jean-Jacques Body, Alex Rider, et al.
Plos One|April 4, 2024
Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancerTarun Mehra, Judith E Lupatsch, Thibaud Kössler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 18, 2016
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 TestingKlazien Matter-Walstra, Matthias Schwenkglenks, Stefan Aebi, et al.
Plos One|December 12, 2024
Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancerTarun Mehra, Judith E Lupatsch, Thibaud Koessler, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2017
Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancerPanagiotis Samaras, Marina Tusup, Thi Dan Linh Nguyen-Kim, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Clinical Colorectal Cancer|October 1, 2016
Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term OutcomeViviane Hess, Ralph Winterhalder, Roger von Moos, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 24, 2014
Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agentsDonald L Patrick, Charles S Cleeland, Roger von Moos, et al.
Onkologie|February 23, 2013
A phase I study of the oral platinum agent satraplatin in combination with oral vinorelbine in patients with advanced solid malignanciesElisa Gallerani, Richard Cathomas, Cristiana Sessa, et al.
Journal of Bone Oncology|January 11, 2019
A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in EuropeJean-Jacques Body, Roger von Moos, Alex Rider, et al.
BMJ Open|April 18, 2023
Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)Stefanie Hayoz, Benjamin Kasenda, Annina Lea Schenker, et al.
Journal of Bone Oncology|June 13, 2018
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countriesRoger von Moos, Jean-Jacques Body, Alex Rider, et al.
Plos One|April 4, 2024
Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancerTarun Mehra, Judith E Lupatsch, Thibaud Kössler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 18, 2016
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 TestingKlazien Matter-Walstra, Matthias Schwenkglenks, Stefan Aebi, et al.
Plos One|December 12, 2024
Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancerTarun Mehra, Judith E Lupatsch, Thibaud Koessler, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2017
Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancerPanagiotis Samaras, Marina Tusup, Thi Dan Linh Nguyen-Kim, et al.
Pageof 13